Shots:

• Incyte to receive an up front & is eligible to receive development, regulatory & commercial milestones along with royalties on net sales of the licensed product in CMS’ territory
• CMS to get an exclusive license to develop & commercialize the product and a non-exclusive license to manufacture ruxolitinib & other topical formulations for autoimmune & inflammatory dermatologic diseases in mainland China, Hong Kong, Macau, Taiwan & certain countries in Southeast Asia
• The collaboration uses Incyte’s Dermatology expertise to advance ruxolitinib for immune-mediated dermatologic conditions. If ruxolitinib is approved, it will be an innovative therapeutic option & provide an access to patients & healthcare providers for treatment in Greater China

Ref: Businesswire | Image: Incyte